Interesting CRSP Put Options For February 20th

The $50 put on CRISPR Therapeutics (CRSP) is bidding $2.20; selling-to-open would net the seller a premium and create an effective purchase basis of $47.80 versus the current share price of $54.92 (≈9% out-of-the-money). Analytical probabilities put a ~71% chance the contract expires worthless, which would deliver a 4.40% return on the cash commitment (34.91% annualized); implied volatility on the put is 64% versus a 12-month realized volatility of 61%, framing this as a yield-enhancing short-put trade with assignment risk.

Analysis

Market structure: The $50 CRSP put trade (collect $2.20, cost basis if assigned $47.80 vs spot $54.92) benefits option sellers capturing a 4.40% cash return (34.9% annualized) if the contract expires worthless; buyers of protection (puts) benefit if downside events occur. This is idiosyncratic to CRSP and barely moves broader markets, but concentrated put selling will compress near-term implied volatility and attract yield-seeking capital into biotech-specific option flows over the next 30–90 days.

Risk assessment: Tail risks are classic biotech binaries — negative trial/FDA outcomes or emergent safety issues could drop CRSP >40% in days, turning a 9% OTM put into assignment fast; implied vol at 64% vs realized 61% means modest premium but can gap higher (>80%) around catalysts. Immediate horizon (days) is option gamma and assignment risk; short-term (weeks–months) is IV re-pricing around news; long-term (quarters) depends on clinical progress and funding environment.

Trade implications: Direct plays: cash-secured $50 put sells for yield or a defined-risk $50/$45 put spread to cap downside. Pair trade: long CRSP vs short XBI/IBB to isolate idiosyncratic upside while hedging sector beta. Options strategies: favor selling premium on 30–90 day tenors when IV > realized by >5–10 pts; rotate to long-dated calls if positive trial readouts reduce IV.

Contrarian angles: The consensus understates assignment convenience — being assigned at $47.80 is an effective accumulation strategy if you want shares below $55; conversely, if macro risk-off spikes, the trade can flip to a loss fast. Mispricing exists when IV > realized by >10 pts or when market liquidity thins; historical parallels (biotech post-binary sell-offs) show buying through staged assignment often outperforms panic buying.

Key Decisions for Investors

• Establish a small, cash-secured short put program: sell CRSP $50 puts (collect ~$2.20) sized to 1–2% of portfolio notional per strike, limit total exposure to 4–6% of portfolio, target expiries 30–90 days; accept assignment at $47.80 and, if assigned, scale to a 2–3% long position.
• Use defined-risk credit spreads if unwilling to be assigned: sell CRSP $50/$45 put spreads for net credit (target net credit ≥ $1.00–$1.50 depending on market), capping max loss to ~$3.50–$4.00 per share; size spreads to 2% portfolio risk.
• Deploy a relative-value pair: go long CRSP (or be long via assigned shares) and short 50–70% notional of XBI or IBB to neutralize sector beta; rebalance monthly and trim if CRSP outperforms sector by >15% in 60 days.
• Risk limits & triggers: immediately close or hedge positions if CRSP gaps below $45 on daily close, or if IV rises above 80% (re-evaluate); take profits or roll spreads if premium decays 50% before expiry or if IV compresses by >15 pts.
• Catalyst monitoring (actionable): monitor upcoming CRSP clinical/FDA calendar over next 30–180 days and institutional block trades; pause new short-put sells 10 trading days ahead of any announced data release or major investor presentations.